JASCAYD

Launch

nerandomilast

NDAORALTABLETPriority Review
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
8

Clinical Trials (5)

NCT07366034Phase 3Not Yet Recruiting

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease

Started Jul 2026
35 enrolled
Fibrosing Interstitial Lung Disease
NCT07201922Phase 3Recruiting

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Started Feb 2026
80 enrolled
Familial Pulmonary FibrosisInterstitial Lung AbnormalitiesInterstitial Lung Diseases
NCT06806592Phase 3Recruiting

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Started Sep 2025
400 enrolled
Interstitial Lung DiseasesSystemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
NCT07081932Phase 1Completed

A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood

Started Aug 2025
16 enrolled
Healthy
NCT07100964Phase 1Completed

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Nerandomilast in the Blood

Started Aug 2025
16 enrolled
Healthy